Drug Trial Radar · NCT06673238
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
95
Actual
Start
Oct 29, 2024
Primary completion
Jun 25, 2026
Study completion Jun 25, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, first-in-human study to investigate safety, tolerability, and pharmacokinetics of ABBV-722 after oral dosing in healthy adult participants.
Conditions
- Healthy Volunteer
Interventions
ABBV-722Drug
Oral Capsule
PlaceboDrug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events Reported During Safety EvaluationsTime frame: Up to Day 44
- Maximum Plasma Concentration (Cmax) of ABBV-722Time frame: Up to Day 21
- Time to Cmax (Tmax) of ABBV-722Time frame: Up to Day 21
- For Parts 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time 0 to Time t (AUCt) of ABBV-722Time frame: Up to Day 8
- For Parts 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf) of ABBV-722Time frame: Up to Day 8
- For Part 3: Observed Plasma Concentration at the End of the Dosing Interval (Ctrough) of ABBV-722Time frame: Up to Day 21
- For Part 3: AUC from Time 0 to the End of Dosing Interval (AUCtau) Following the First and Last Doses of ABBV-722Time frame: Up to Day 21
- Terminal Phase Elimination Rate Constant (Beta) of ABBV-722Time frame: Up to Day 21
- Terminal Phase Elimination Half-Life (t1/2) of ABBV-722Time frame: Up to Day 21
- Dose Normalized CmaxTime frame: Up to Day 21
- Dose Normalized AUCsTime frame: Up to Day 21
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Altasciences Clinical Los Angeles /ID# 280183
Cypress, California
Acpru /Id# 270279
Grayslake, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.